Q-Microcueticals Lipo-Active Rapid Relief 60s - Effective Results for Pain & Inflammation!

Q-Microcueticals Lipo-Active Rapid Relief 60s - Effective Results for Pain & Inflammation!

  • R 655.00
    Unit price per 
Tax included. Shipping calculated at checkout.


INDICATIONS: A uniquely powerful 4-in-1 formulation, the ingredients are known to support joints, neuropathy, vascular health and carbohydrate metabolism; may be useful for metabolic syndrome support. L-citrulline supports nitric oxide production in the body, helping to reduce ammonia and uric acid build-up. Liposomal Glutathione provides essential antioxidant support to reduce inflammation caused by radical oxygen species (R.O.S). Gabapentin helps regulate the activity of neurotransmitters, providing supportive neuropathy and muscle pain relief, Benfotiamine (B1) helps manage carbohydrate metabolism and the reduction of oxidants that cause inflammation.

DOSAGE AND DIRECTIONS FOR USE:

Adults & Children Over 12 years of age: Take 1-2 capsules, twice daily on an empty stomach or as directed by your healthcare practitioner. Reduce dose as symptoms resolve.

Gene Information: Known support for  NOS, PEMT, GSTM1, GSTT1, GSTP1, liver detoxification and cellular waste removal.

CONTRAINDICATIONS: Not tested for suitability for pregnant or lactating women. Use with caution and under medical supervision, if taking antihypertensive (BP) or phosphodiesterase inhibitor (ED) drugs. Keep out of reach of children. Do not take if sensitive to any of the ingredients.

WARNING: Do not exceed the recommended dosage. Consult your doctor if symptoms persist.

COMPOSITION: Benfotiamine (B1) - 250mg, Gabapentin - 50mg, Glutathione (GSH)-Phospholipids Liposome - 350mg (providing 200mg reduced Glutathione), L-Citrulline - 100mg.

STATEMENTS: Not tested on animals. Free from wheat, gluten, yeast, colouring, flavouring and preservatives. Vegan friendly. Category D: Health supplement. This product is not intended to diagnose, treat, cure or prevent any disease. This unregistered product and statements have not been evaluated by SAPHRA.